Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Jaguar Health, Inc. (JAGX)

4.7   0.19 (4.21%) 01-27 16:00
Open: 4.47 Pre. Close: 4.51
High: 4.77 Low: 4.45
Volume: 311,528 Market Cap: 9(M)

Technical analysis

as of: 2023-01-27 4:45:41 PM
Overall:       
Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 7.18     One year: 8.38
Support: Support1: 2.39    Support2: 0.08
Resistance: Resistance1: 6.15    Resistance2: 7.18
Pivot: 1.69
Moving Average: MA(5): 4.9     MA(20): 1.29
MA(100): 0.37     MA(250): 0.39
MACD: MACD(12,26): 1.1     Signal(9): 0.6
Stochastic oscillator: %K(14,3): 76.4     %D(3): 79
RSI: RSI(14): 83.4
52-week: High: 6.15  Low: 0.08
Average Vol(K): 3-Month: 7,928 (K)  10-Days: 10,590 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ JAGX ] has closed below upper band by 17.1%. Bollinger Bands are 2061.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 4.77 - 4.8 4.8 - 4.82
Low: 4.4 - 4.42 4.42 - 4.44
Close: 4.66 - 4.7 4.7 - 4.74

Company Description

Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic, and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer for multiple possible follow-on indications, including cancer therapy-related diarrhea; orphan-drug indications for symptomatic relief of diarrhea in infants and children with congenital diarrheal disorders and for adult and pediatric patients for short bowel syndrome with intestinal failure with; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops lechlemer, a second-generation anti-secretory agent for cholera; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. Jaguar Health, Inc. was founded in 2013 and is headquartered in San Francisco, California.

Headline News

Thu, 26 Jan 2023
Jaguar Health to submit application to begin trial for ultra-rare ... - Seeking Alpha

Tue, 24 Jan 2023
Here's Why Jaguar Health (JAGX) Stock Is Volatile Tuesday - Benzinga

Mon, 23 Jan 2023
Why Is Intelligent Bio Solutions (INBS) Stock Up 363% Today? - InvestorPlace

Mon, 23 Jan 2023
Is Jaguar Health (JAGX) Stock Really Up 6800%? - InvestorPlace

Mon, 23 Jan 2023
Jaguar Health (NASDAQ:JAGX) Is Carrying A Fair Bit Of Debt - Simply Wall St

Fri, 20 Jan 2023
Thinking about buying stock in Salarius Pharmaceuticals ... - PR Newswire

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Neutral
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 151 (M)
Shares Float 130 (M)
% Held by Insiders 19.4 (%)
% Held by Institutions 3.9 (%)
Shares Short 8,470 (K)
Shares Short P.Month 6,630 (K)

Stock Financials

EPS -1.3
EPS Est Next Qtl -0.08
EPS Est This Year -0.69
EPS Est Next Year -0.22
Book Value (p.s.) 0.02
Profit Margin (%) 0
Operating Margin (%) -361.5
Return on Assets (ttm) -44.1
Return on Equity (ttm) -433.3
Qtrly Rev. Growth 400
Gross Profit (p.s.) 0.01
Sales Per Share 0.07
EBITDA (p.s.) -0.25
Qtrly Earnings Growth 0
Operating Cash Flow -36 (M)
Levered Free Cash Flow -14 (M)

Stock Valuations

PE Ratio -3.63
PEG Ratio 0
Price to Book value 156.66
Price to Sales 65.93
Price to Cash Flow -19.97

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date 2019-06-06
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.